.svg)
Wherever you are on the R&D journey and whatever part you play, we equip you with a therapeutic ecosystem perspective that will give you an edge.
Wherever you are on the R&D journey, we can help
Explore how we have helped others
.svg)
See our work in action
We help teams (across all parts of the business) by providing targeted and referenced information that is recent, reliable and relevant. We shine a light on the movers and shakers in your chosen therapeutic area - the people, bodies, groups and events that shape how an innovation is developed, approved and launched effectively.
Whatever your need, we are able to search out the best people to give you these answers and a great deal more.
Medical, educational and commercial questions abound.
Wherever you are in late development, knowing who the early adopters are is a critical success factor.
After all the years of hard work:
It’s complicated. Very. But we can help you find the support you need – by finding you the right people to talk to.
“We are conducting a scientific due diligence of an asset that’s available for purchase in the next six weeks. We need to speak with people with experience of this technology in this area.”
“We have no experience, and therefore no corporate wisdom, in this therapeutic condition. We would like to talk to people who have worked with regulators and reimbursement agencies in this space.”
“We have just acquired a company and there are assets in their pipeline in areas that we have no experience in. We need to find experts in these areas who can give us an independent view on their attractiveness and potential.”
“I am completely new to this area. I have assumed global responsibility for this product, but I have no idea of who’s who; or where to go; or who I should speak to; or what’s really happening in this area.”
“We are about three years away from launch. We know we need to engage with patient groups in this area – they will be important voices when we launch; today, we have no relationship with them.”
“We have had the only approved treatment for this condition for the past seven years. In the next three, we know of four new products that will be launched. We need to be sure that we have a clear and unbiased view of the therapeutic condition – complacency is one of our biggest threats.”
“Our product is complex. There are many rules about when and how it may be used. Its complexity may put off prescribers and patients if we are not careful. We need to engage with the rising stars who are comfortable with this type of technology. We need their support to train their peers and patients.”
“Our Medical Division has set an ambitious goal to run 12 International and Continental advisory boards in the next 18 months. The issue we’re having is deciding who to invite to each event, there are many competing opinions. We just need a more evidence-based approach.”
“We launched our product 18 months ago. Our performance does not match our expectations. We would like to dive deeper into a single market, to find the people who are interested in our therapeutic condition at a local level. We are trying to find new people to talk to.”
.svg)
.svg)
.svg)